The DOI matches its Crossref record; 46 of the 51 references it cites were found in a registry or an index.
The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies
Open accessAbstract
BACKGROUND: Recent studies of pemetrexed have identified a predictive role for non-small cell lung cancer (NSCLC) histology. We further reviewed the differential efficacy of pemetrexed according to histology in two large, phase III NSCLC trials. METHODS: One study tested pemetrexed versus docetaxel in previously treated patients (n = 571) and the other tested cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemotherapy-naive patients (n = 1,725) with advanced NSCLC. Cox proportional hazard models were used to test for covariate-adjusted treatment-by-histology interactions (THIs) for overall survival (OS) and progression-free survival (PFS). For each histologic subgroup, the Kaplan-Meier method was used to estimate unadjusted within-arm medians, and Cox models were used to estimate covariate-adjusted between-arm hazard ratios (HRs). RESULTS: In both studies, treatment arms were well balanced for histology. THIs were statistically significant (p < .005) for both OS and PFS. Nonsquamous patients treated with pemetrexed-based therapy experienced longer survival than the comparators (HR, 0.78 and 0.84, respectively), whereas squamous patients had shorter survival (HR, 1.56 and 1.23, respectively). Whereas the efficacy of pemetrexed regimens differed according to histology, it did not differ for docetaxel or for cisplatin plus gemcitabine. Pemetrexed was well tolerated across histologic groups. CONCLUSIONS: The consistency of these results across studies confirms the predictive effect of histology for pemetrexed and the survival advantage for pemetrexed in patients with nonsquamous histology. These analyses suggest pemetrexed should not be recommended for the treatment of squamous cell carcinoma, but, because of efficacy and safety advantages, pemetrexed may be preferable to other agents for treatment of patients with nonsquamous NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a retrospective analysis, a predictive impact of histology on outcome by pemetrexed was reported favouring those patients with NSCC (median OS: 8.0 versus 9.3 months, docetaxel versus pemetrexed, HR 0.78, 95% CI: 0.61-1.0,P = 0.004) [56].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,524
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citationScagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
Self-citationFukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,871
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Self-citationThatcher, N., Chang, A., Parikh, P., Rodrigues Pereira, J., Ciuleanu, T., von Pawel, J., Thongprasert, S., Tan, E. H., Pemberton, K., Archer, V., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67625-8 · Cited by 2,079
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,948
Spiess, P. E., Lee, A. K., Leibovici, D., Wang, X., Do, K.-A., & Pisters, L. L. (2006) · Cancer · doi:10.1002/cncr.21979 · Cited by 1,930
Cancer: Principles and Practice of Oncology.
(1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-3-506_5 · Cited by 1,913
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
Tsao, M., Sakurada, A., Cutz, J.-C., Zhu, C., Kamel‐Reid, S., Squire, J. A., Lorimer, I. A. J., Zhang, T., Liu, G., Daneshmand, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050736 · Cited by 1,815
Self-citationLung cancer in never smokers — a different disease
Sun, S., Schiller, J. H., & Gazdar, A. F. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2190 · Cited by 1,601
Pao, W. J., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 637
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
Green, S., & Weiss, G. R. (1992) · Investigational New Drugs · doi:10.1007/bf00944177 · Cited by 601
Prognostic Factors in Non-small Cell Lung Cancer
Brundage, M., Davies, D. L., & Mackillop, W. J. (2002) · CHEST Journal · doi:10.1378/chest.122.3.1037 · Cited by 564
Shih, C., Chen, V. J., Gossett, L. S., Gates, S. B., MacKellar, W. C., Habeck, L. L., Shackelford, K. A., Mendelsohn, L. G., Soose, D. J., Patel, V. F., et al. (1997) · PubMed · Cited by 560
Ceppi, P., Volante, M., Saviozzi, S., Rapa, I., Novello, S., Cambieri, A., Iacono, M. L., Cappia, S., Papotti, M. G., & Scagliotti, G. V. (2006) · Cancer · doi:10.1002/cncr.22208 · Cited by 361
Self-citationHirsch, F. R., Spreafico, A., Novello, S., Wood, M. D., Simms, L., & Papotti, M. G. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318189f551 · Cited by 219
Self-citationGiovannetti, E., Mey, V., Nannizzi, S., Pasqualetti, G., Marini, L., Tacca, M. D., & Danesi, R. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.009373 · Cited by 179
Cohen, E. E. W., & Vokes, E. E. (2003) · Springer eBooks · doi:10.1007/978-3-642-55780-4_28 · Cited by 172
Sigmond, J., Backus, H. H. J., Wouters, D., Temmink, O. H., Jansen, G., & Peters, G. J. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00287-9 · Cited by 147
Ohe, Y., Ichinose, Y., Nakagawa, K., Tamura, T., Kubota, K., Yamamoto, N., Adachi, S., Nambu, Y., Fujimoto, T., Nishiwaki, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5143 · Cited by 120
Peterson, P. M., Park, K., Fossella, F. V., Gatzemeier, U., John, W. J., & Scagliotti, G. V. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000284677.33344.62 · Cited by 110
Self-citationEnzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.
Mendelsohn, L. G., Shih, C., Chen, V. J., Habeck, L. L., Gates, S. B., & Shackelford, K. A. (1999) · PubMed · Cited by 103
Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study
Ciuleanu, T., Brodowicz, T., Belani, C. P., Kim, J., Krzakowski, M. J., Laack, E., Wu, Y.-L. L. C., Peterson, P. M., Adachi, S., & Zielinski, C. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8011 · Cited by 98
Self-citationSchultz, R. M., Vj, C., Bewley, J. R., Roberts, E. F., Shih, C., & Dempsey, J. A. (1999) · PubMed · Cited by 93
Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors
Ceppi, P., Volante, M., Ferrero, A., Righi, L., Rapa, I., Rosas, R., Berruti, A., Dogliotti, L., Scagliotti, G. V., & Papotti, M. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1513 · Cited by 85
Self-citationSalon, C., Merdzhanova, G., Brambilla, C., Brambilla, E. M., Gazzéri, S., & Eymin, B. (2007) · Oncogene · doi:10.1038/sj.onc.1210499 · Cited by 70
Einhorn, L. H. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2056 · Cited by 58
Schmid, M., Sen, M., Rosenbach, M., Carrera, C. J., Friedman, H. S., & Carson, D. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203942 · Cited by 57
Sowers, R. S., Toguchida, J., Qin, J., Meyers, P. A., Healey, J. H., Huvos, A. G., Banerjee, D., Bertino, J. R., & Gorlick, R. G. (2003) · PubMed · Cited by 53
Grønberg, B. H., Bremnes, R. M., Aasebø, U., Brunsvig, P. F., Fløtten, Ø., Amundsen, T., von Plessen, C., Wang, M., & Sundstrøm, S. H. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.04.003 · Cited by 30
Scagliotti, G. V., Purvish, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Simms, L., Sugarman, K. P., Obasaju, C. K., & Blatter, J. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283088.78970.9b · Cited by 28
Self-citationA phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer
Giaccone, G., Chevalier, T. L., Thatcher, N., Smit, E. F., Janmaat, M. L., Rodríguez, J., Oulid-Aïssa, D., & Soria, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.7073 · Cited by 28
Lynch, T. J., Bell, D., Haber, D. A., Johnson, D., Giaccone, G., Fukuoka, M., Kris, M. G., Herbst, R. S., Krebs, A., & Ochs, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.7006 · Cited by 24
Chattopadhyay, S., Zhao, R., Tsai, E., Schramm, V. L., & Goldman, I. D. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0313 · Cited by 17
Peng, G., Zinner, R., Wang, Y., Treat, J., Monberg, M., Obasaju, C. K., Herbst, R. S., Novello, S., & Scagliotti, G. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8096 · Cited by 17
Self-citationHanna, N. H., Ansari, R., Bhatia, S., Govindan, R., Bruetman, D., Hosford, M., Fisher, W. B., White, A., Breen, T., & Juliar, B. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7063 · Cited by 14
Self-citationScagliotti, G. V., Kaiser, C. J., Biesma, B., Manegold, C., Gatzemeier, U., Serwatowski, P., Syrigos, K., Bálint, B., Smit, H. J. M., & Vansteenkiste, J. (2007) · Journal of Thoracic Oncology · doi:10.1097/01.jto.0000283223.48520.7c · Cited by 13
Self-citationSmit, E. F., Socinski, M. A., Mullaney, B. P., Myrand, S. P., Powell, E., Lorigan, P. C., Kaiser, C., Guba, S. C., & Thatcher, N. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8030 · Cited by 13
Pujol, J. L., Shaharyar, S., Kortsik, C., Wu, M.-N., Bagnes, C., Barata, F. J., Kayitalire, L., Hong, S. H., Shepherd, F. A., & Fossella, F. V. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.7135 · Cited by 13
Self-citationPimentel, F. L., von Pawel, J., Martins, R. G., Novello, S., Douillard, J., O’Brien, M., Liepa, A. M., & Simms, L. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8097 · Cited by 8
Self-citationE2F1 overexpression associated with TS and survivin gene expressions in non-small cell lung cancer
Huang, C., Liu, D., Nakano, J., Ishikawa, S., Yokomise, H., & Ueno, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7669 · Cited by 6
Flagged first, then by citations
5 of the 51 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Jiroutek, 1998, Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981–1992, Proc Am Soc Clin Oncol, 17, 461a
- National Cancer Institute, 1999, Common Toxicity Criteria v2.0 (CTC)
Cited by
Sorted by citations
Travis, W. D., Brambilla, E. M., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Schil, P. E. V., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,834
Self-citationMitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Metadata
- Authors
- Scagliotti, G., Hanna, N., Fossella, F., Sugarman, K., Blatter, J., Peterson, P., Simms, L., & Shepherd, F. A.
- Affiliations
- University of Turin (IT)
- Indiana University Indianapolis (US)
- The University of Texas MD Anderson Cancer Center (US)
- Eli Lilly (United States) (US)
- Eli Lilly (Germany) (DE)
- Eli Lilly (Canada) (CA)
- University of Toronto (CA)
- Corresponding author
- Scagliotti, Giorgio
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-02-16
- Volume
- 14
- Issue
- 3
- Pages
- 253-263
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2139939379
- Cited by
- 690
- References
- 51
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 10 · 2023: 15 · 2022: 21 · 2021: 15 · 2020: 27 · 2019: 29 · 2018: 30 · 2017: 42 · 2016: 46 · 2015: 41 · 2014: 69 · 2013: 72 · 2012: 71
- FWCI
- 72.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- The Oncologist (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- pemetrexed, non-small cell lung cancer, tumor histology, squamous cell carcinoma, docetaxel, overall survival, progression-free survival, predictive biomarkers
- MeSH terms
- Pemetrexed, Docetaxel, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Deoxycytidine, Female, Glutamates, Guanine, Humans, Lung Neoplasms, Male, Middle Aged, Randomized Controlled Trials as Topic, Taxoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
